Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Split, Croatia, Jan. 10, 2024 (GLOBE NEWSWIRE) -- DegenX - a 100% DAO-owned and controlled multi-chain DeFi ecosystem - launched LinkBridge, a cross-chain bridge connecting DGNX to Ethereum. This...
-
New York, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Corrugated packaging involves the use of corrugated boards to create boxes and containers for packaging various goods. These materials provide strength,...
-
Singapore, Jan. 09, 2024 (GLOBE NEWSWIRE) -- XT.COM, the world’s first socially infused trading platform, is thrilled to announce the listing of PLAYA3ULL GAMES(3ULL) on its platform in the...
-
ORLANDO, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Abacus Life, Inc. (NASDAQ: ABL) (“Abacus” or the “Company”), a leading buyer of life insurance policies and vertically integrated alternative asset...
-
Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "3-day Mini MBA for In-house Lawyers Training Course" has been added to ResearchAndMarkets.com's offering. Leadership and management skills are a...
-
Manchester, England, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The $BabyMyro Token is gunning for the top spot amongst BSC dog-themed tokens. Its approach is to attract all dog lovers with the adorableness...
-
CEO’s False Narrative Designed to Hide His Ineffective Leadership, Lack of Vision and High-Risk Go-Forward Strategy Questionable Behaviors Underscore Why New Leadership is Required for Gildan to...
-
New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- The global exosomes market size is slated to expand at ~16% CAGR between 2024 and 2036. The market is poised to garner a revenue of USD 5.3 billion by the...
-
Dublin, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The "Global Epigenetics Market by Product & Service (Enzymes (DNA-modifying Enzymes), Kits & Reagents (Antibodies), Instrument, Software), Method...
-
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address...